NEW YORK (GenomeWeb News) – Gene Network Sciences has struck a research agreement with The University of Texas MD Anderson Cancer Center that will focus on translating DNA sequencing and clinical data from patients with glioblastoma into discoveries that could lead to diagnostics and drugs.
The collaboration will analyze genetic, genomic, and clinical endpoint data from MD Anderson using GNS' Reverse Engineering and Forward Simulation software.
GNS said that the analyses should generate models that enable discovery of genes, proteins, and other entities that drive the progress and recurrence of glioblastoma, as well as patient survival. The partners believe the research will lead to the identification of new combination drug targets for disease and the development of diagnostics to determine individual treatments.
GNS and MD Anderson will transform the data into computer models that link genetic alterations to changes in gene expression, and will be used to identify novel drug targets and response biomarkers that could identify the optimal single or combination drug therapy.
"There continues to be an urgent need for a more efficient translation of research into improved treatments for glioblastoma patients," MD Anderson's Department of Pathology Associate Professor, Kenneth Aldape, said in a statement.
Financial terms of the agreement were not released.